October 28, 2025 10:38 am EDT

• NuvaRing ^® (etonogestrel with ethinylestradiol contraceptive vaginal ring) is a contraceptive vaginal ring used to prevent pregnancy.¹

---

Sydney, Australia, 27 OCTOBER 2025 – Organon’s NuvaRing^® (etonogestrel with ethinylestradiol contraceptive) vaginal ring (3 pack) will be listed on the Pharmaceutical Benefits Scheme (PBS), providing an additional affordable contraceptive option for Australian women from 1 November 2025.

NuvaRing is a prescription contraceptive method in the form of a controlled-release contraceptive ring for vaginal use that releases two hormones – etonogestrel (a progestogen) and ethinylestradiol (an oestrogen).¹ It is used for three weeks in a row before being removed for one week before a new ring is inserted. ¹

Dr Sara Whitburn, Medical Director, Sexual Health Victoria says, “expanding the range of affordable contraceptive options by adding NuvaRing to the PBS helps increase contraceptive choice by reducing the cost barriers that may prevent women from finding the type of contraception that works best for them”.

Daile Kelleher, Chief Executive Officer, Sexual and Reproductive Health Australia (SRHA), says “Contraception is essential healthcare, not a luxury item. Everyone deserves the right to access affordable contraceptive options and to choose the method that best fits their life, without barriers such as cost. SRHA welcome the PBS listing of NuvaRing and thanks the Federal Government for supporting greater equity in sexual and reproductive health care for all Australians.”

Mr. Bilal Somra, Managing Director, Organon ANZ, says, “NuvaRing’s availability on the PBS provides an additional affordable contraceptive option for Australian women and is a demonstrated example of the Government’s meaningful commitment to supporting the health and wellbeing of Australian women”.

Important NuvaRing Safety Information¹

Contraindications: NuvaRing should not be used if the person is allergic to ethinylestradiol or etonogestrel, or any of the ingredients of NuvaRing; have or have ever had a disorder affecting the blood vessels, heart attack, stroke, or a condition that may be a first sign of a heart attack or stroke; serious risk factors for blood clots or a blood clotting disorder; major surgery; migraine with aura; diabetes with damaged blood vessels; pancreatitis; jaundice or severe liver disease; unexplained vaginal bleeding; cancer of the breast or genital organs; liver tumor; pregnant; taking certain hepatitis C medicines.

Precautions: NuvaRing does not protect against HIV infections (AIDS) and other sexually transmitted diseases.

Side effects: All medicines can have side effects.Common side effects include abdominal pain, nausea, yeast infection in vagina (such as thrush), vaginal discomfort due to the ring, genital itching, secretion from the vagina, headache or migraine, low mood, lower sex drive, breast pain, painful periods, acne, weight gain and the ring falling out. Serious side effects include blood clots in a vein or artery and cancer.

Interactions: Concomitant administration of NuvaRing and other medicines may lead to breakthrough bleeding and/or contraceptive failure. These may include medicines used to treat epilepsy, tuberculosis, HIV infection, Hepatitis C virus infection, other infectious diseases and pulmonary hypertension. NuvaRing can also affect how other medicines work. 

As a prescription medicine, only healthcare professionals, in consultation with their patients, can determine the most appropriate treatment options. For more information about the medicine, see the Consumer Medicine Information available here.

Dr. Sara Whitburn and Daile Kelleher have participated in Expert Input Forums, and Dr. Sara Whitburn has additionally engaged in local and regional medical education initiatives for Organon, for which they received compensation at fair market value. For this Organon media announcement, no compensation was provided to Dr Sara Whitburn or Daile Kelleher, and the opinions expressed are their own.

About Organon

Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialise their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey, United States of America.

© (2025) Organon group of companies.  All rights reserved. Organon and the Organon logo are trademarks of the Organon group of companies.

Organon ANZ, level 5, 66 King St, Sydney NSW 2000. AU-TRL-110030. First issued October 2025.

For more information, visit www.organon.com/australia or connect with us on LinkedIn at @OrganonANZ.

Reference

1. NuvaRing Consumer Medicine Information. Last accessed: October 2025. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-CMI-01652-1&d=20251022172310101